Compare ALEMBIC PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA CIPLA ALEMBIC PHARMA/
CIPLA
 
P/E (TTM) x 16.0 28.5 56.3% View Chart
P/BV x 6.4 4.0 158.5% View Chart
Dividend Yield % 0.6 0.5 117.7%  

Financials

 ALEMBIC PHARMA   CIPLA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
CIPLA
Mar-20
ALEMBIC PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs664586 113.4%   
Low Rs412357 115.6%   
Sales per share (Unadj.) Rs208.7207.0 100.8%  
Earnings per share (Unadj.) Rs31.018.6 166.7%  
Cash flow per share (Unadj.) Rs37.133.2 111.9%  
Dividends per share (Unadj.) Rs5.504.00 137.5%  
Dividend yield (eoy) %1.00.8 120.4%  
Book value per share (Unadj.) Rs144.2195.5 73.8%  
Shares outstanding (eoy) m188.52806.35 23.4%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x2.62.3 113.3%   
Avg P/E ratio x17.425.3 68.5%  
P/CF ratio (eoy) x14.514.2 102.1%  
Price / Book Value ratio x3.72.4 154.8%  
Dividend payout %17.721.5 82.5%   
Avg Mkt Cap Rs m101,461379,912 26.7%   
No. of employees `000NA25.8 0.0%   
Total wages/salary Rs m7,46730,270 24.7%   
Avg. sales/employee Rs ThNM6,459.6-  
Avg. wages/employee Rs ThNM1,171.2-  
Avg. net profit/employee Rs ThNM580.2-  
INCOME DATA
Net Sales Rs m39,347166,949 23.6%  
Other income Rs m943,442 2.7%   
Total revenues Rs m39,441170,391 23.1%   
Gross profit Rs m8,73632,060 27.2%  
Depreciation Rs m1,15211,747 9.8%   
Interest Rs m1841,974 9.3%   
Profit before tax Rs m7,49321,782 34.4%   
Minority Interest Rs m11-475 -2.3%   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5686,312 24.8%   
Profit after tax Rs m5,84414,995 39.0%  
Gross profit margin %22.219.2 115.6%  
Effective tax rate %20.929.0 72.2%   
Net profit margin %14.99.0 165.4%  
BALANCE SHEET DATA
Current assets Rs m19,577117,038 16.7%   
Current liabilities Rs m14,89643,931 33.9%   
Net working cap to sales %11.943.8 27.2%  
Current ratio x1.32.7 49.3%  
Inventory Days Days9096 93.8%  
Debtors Days Days4585 53.3%  
Net fixed assets Rs m27,097107,424 25.2%   
Share capital Rs m3771,613 23.4%   
"Free" reserves Rs m26,811156,018 17.2%   
Net worth Rs m27,188157,630 17.2%   
Long term debt Rs m4,99323,693 21.1%   
Total assets Rs m47,778236,626 20.2%  
Interest coverage x41.712.0 346.5%   
Debt to equity ratio x0.20.2 122.2%  
Sales to assets ratio x0.80.7 116.7%   
Return on assets %12.67.2 175.9%  
Return on equity %21.59.5 225.9%  
Return on capital %23.612.8 183.8%  
Exports to sales %033.0 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,175 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45356,036 34.7%   
Fx outflow Rs m6,0656,764 89.7%   
Net fx Rs m13,38849,272 27.2%   
CASH FLOW
From Operations Rs m8,12030,685 26.5%  
From Investments Rs m-7,5561,040 -726.3%  
From Financial Activity Rs m590-29,488 -2.0%  
Net Cashflow Rs m1,1532,340 49.3%  

Share Holding

Indian Promoters % 74.1 16.0 463.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 2.9 12.2 23.8%  
FIIs % 9.1 23.7 38.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 13.9 26.2 53.1%  
Shareholders   49,328 161,166 30.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON   IPCA LABS  JUBILANT LIFE SCIENCES  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended deep in the red.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 26, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS